Icahn School of Medicine at Mount Sinai
mssm.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
760
Active
206
Phase 3
29
Total enrollment
383,624
Pipeline matrix
Showing 40 of 87 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Methylphenidate | — | — | — | 5 | |||
| Ketamine | — | — | — | 9 | |||
| Atomoxetine | — | — | — | — | 4 | ||
| Olanzapine | — | — | — | — | — | 2 | |
| Dexmedetomidine | — | — | — | — | — | 2 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Bevacizumab | — | — | — | — | — | 1 | |
| Ephedrine | — | — | — | — | — | 1 | |
| Normal Saline Placebo | — | — | — | — | — | 1 | |
| Clonazepam | — | — | — | — | — | 1 | |
| Buprenorphine | — | — | — | — | — | 1 | |
| Chlorthalidone | — | — | — | — | — | 1 | |
| Remimazolam | — | — | — | — | — | 1 | |
| Cannabidiol | — | — | — | 4 | |||
| Suzetrigine | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | 5 | ||
| Antiplatelet-only strategy | — | — | — | — | — | 1 | |
| Oral Anticoagulant plus background antiplatelet therapy | — | — | — | — | — | 1 | |
| Misoprostol | — | — | — | — | — | 1 | |
| Pitocin | — | — | — | — | — | 1 | |
| SAFE | — | — | — | — | — | 1 | |
| Inclisiran | — | — | — | — | — | 1 | |
| Low-dose sirolimus | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 4 | |
| Dupilumab | — | — | — | — | 4 | ||
| Placebos | — | — | — | — | 3 | ||
| Sotagliflozin | — | — | — | — | 2 | ||
| Lupron | — | — | — | — | — | 2 | |
| cisplatin | — | — | — | — | — | 2 | |
| Ritlecitinib | — | — | — | — | — | 2 | |
| Deucravacitinib | — | — | — | — | — | 2 | |
| Abrocitinib | — | — | — | — | 2 | ||
| Pyridostigmine | — | — | — | — | 2 | ||
| Trastuzumab | — | — | — | — | — | 2 | |
| Pertuzumab | — | — | — | — | — | 2 | |
| Darolutamide | — | — | — | — | — | 1 | |
| Methotrexate | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 | |
| Abemaciclib | — | — | — | — | — | 1 | |
| Bicalutamide | — | — | — | — | — | 1 |
47 more active programs hidden
Next readouts
- 2020-04-01
- 2023-02-23
- 2025-05
- 2025-08
- 2025-09
- 2025-09-25
- 2026-02-02
- 2026-03
- 2026-04-01
- 2026-04-15
Top conditions
- Coronary Artery Disease16
- Major Depressive Disorder15
- Prostate Cancer14
- Depression14
- Obesity14
- Mild Cognitive Impairment12
- Asthma11
- Breast Cancer10
Frequently asked questions about Icahn School of Medicine at Mount Sinai
- How many clinical trials does Icahn School of Medicine at Mount Sinai have on ClinicalTrials.gov?
- Icahn School of Medicine at Mount Sinai is listed as the lead sponsor on 760 clinical trials in ClinicalTrials.gov, 206 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Icahn School of Medicine at Mount Sinai's trials are in Phase 3?
- 29 of Icahn School of Medicine at Mount Sinai's trials are in Phase 3, spread across 87 active drug programs.
- What therapeutic areas does Icahn School of Medicine at Mount Sinai focus on?
- Icahn School of Medicine at Mount Sinai's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Major Depressive Disorder, Prostate Cancer, Depression, Obesity.
- When are Icahn School of Medicine at Mount Sinai's next clinical trial readouts?
- Icahn School of Medicine at Mount Sinai has 10 upcoming primary-completion readouts tracked here; the soonest is “The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer”, expected around 2020-04-01.